GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Braxia Scientific Corp (XCNQ:BRAX) » Definitions » COGS-to-Revenue

Braxia Scientific (XCNQ:BRAX) COGS-to-Revenue : 0.83 (As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Braxia Scientific COGS-to-Revenue?

Braxia Scientific's Cost of Goods Sold for the three months ended in Dec. 2023 was C$0.41 Mil. Its Revenue for the three months ended in Dec. 2023 was C$0.49 Mil.

Braxia Scientific's COGS to Revenue for the three months ended in Dec. 2023 was 0.83.

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin. Braxia Scientific's Gross Margin % for the three months ended in Dec. 2023 was 16.67%.


Braxia Scientific COGS-to-Revenue Historical Data

The historical data trend for Braxia Scientific's COGS-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Braxia Scientific COGS-to-Revenue Chart

Braxia Scientific Annual Data
Trend Mar21 Mar22 Mar23
COGS-to-Revenue
0.86 0.83 0.91

Braxia Scientific Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
COGS-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.98 0.95 0.85 0.78 0.83

Braxia Scientific COGS-to-Revenue Calculation

Braxia Scientific's COGS to Revenue for the fiscal year that ended in Mar. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=1.712 / 1.884
=0.91

Braxia Scientific's COGS to Revenue for the quarter that ended in Dec. 2023 is calculated as

COGS to Revenue=Cost of Goods Sold / Revenue
=0.41 / 0.492
=0.83

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Braxia Scientific  (XCNQ:BRAX) COGS-to-Revenue Explanation

Cost of Goods Sold is directly linked to profitability of the company through Gross Margin.

Braxia Scientific's Gross Margin % for the three months ended in Dec. 2023 is calculated as:

Gross Margin %=1 - COGS to Revenue
=1 - Cost of Goods Sold / Revenue
=1 - 0.41 / 0.492
=16.67 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

A company that has a moat can usually maintain or even expand their Gross Margin. A company can increase its Gross Margin in two ways. It can increase the prices of the goods it sells and keeps its Cost of Goods Sold unchanged. Or it can keep the sales price unchanged and squeeze its suppliers to reduce the Cost of Goods Sold. Warren Buffett believes businesses with the power to raise prices have moats.


Braxia Scientific COGS-to-Revenue Related Terms

Thank you for viewing the detailed overview of Braxia Scientific's COGS-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Braxia Scientific (XCNQ:BRAX) Business Description

Traded in Other Exchanges
Address
700 Bay Street, Suite 1903, Toronto, ON, CAN, M5G 1Z6
Braxia Scientific Corp is a research-driven medical solutions company that aims to reduce the illness burden of brain-based mental disorders such as depressive disorder among others. It is primarily focused on owning and operating multidisciplinary clinics, providing treatment for mental health disorders, and research activities related to discovering and commercializing novel drugs and delivery methods. The company develops ketamine and psilocybin derivatives and other psychedelic products from its IP development platform.

Braxia Scientific (XCNQ:BRAX) Headlines

No Headlines